

Konstantin Mechler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577855/publications.pdf>

Version: 2024-02-01

29
papers

362
citations

933410

10
h-index

940516

16
g-index

31
all docs

31
docs citations

31
times ranked

465
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence-based pharmacological treatment options for ADHD in children and adolescents. , 2022, 230, 107940.		68
2	Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior. Psychopharmacology, 2022, 239, 2457-2470.	3.1	2
3	Quantitative retrospective natural history modeling for orphan drug development. Journal of Inherited Metabolic Disease, 2021, 44, 99-109.	3.6	16
4	“Include me if you can” reasons for low enrollment of pediatric patients in a psychopharmacological trial. Trials, 2021, 22, 178.	1.6	4
5	Patterns of extreme temperature-related catastrophic events in Europe including the Russian Federation: a cross-sectional analysis of the Emergency Events Database. BMJ Open, 2021, 11, e046359.	1.9	9
6	Medication Adherence in Adolescents with Psychiatric Disorders. Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2021, 49, 295-306.	0.7	5
7	Actigraphy-Derived Sleep Profiles of Children with and without Attention-Deficit/Hyperactivity Disorder (ADHD) over Two Weeks—Comparison, Precursor Symptoms, and the Chronotype. Brain Sciences, 2021, 11, 1564.	2.3	4
8	Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” a cross-sectional analysis. BMC Medical Ethics, 2020, 21, 20.	2.4	3
9	Structural and functional MRI of altered brain development in a novel adolescent rat model of quinpirole-induced compulsive checking behavior. European Neuropsychopharmacology, 2020, 33, 58-70.	0.7	7
10	FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. PLoS ONE, 2020, 15, e0230898.	2.5	17
11	Intuitive Global Insight Into COVID-19 Clinical Research Activities—The “COVID-19 Map of Hope”, Journal of Clinical Pharmacology, 2020, 60, 826-827.	2.0	3
12	FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898.		0
13	FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898.		0
14	FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898.		0
15	FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898.		0
16	Disasters in Germany and France: An Analysis of the Emergency Events Database From a Pediatric Perspective. Disaster Medicine and Public Health Preparedness, 2019, 13, 958-965.	1.3	11
17	“Drugs Don’t Work in Patients Who Don’t Take Them”, Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2019, 47, 528-534.	0.7	4
18	Screening for ADHD-Related Symptoms in Preschoolers Should Be Considered—Results From a Representative Sample of 5-Year-Olds From a German Metropolitan Region. Frontiers in Psychiatry, 2018, 9, 612.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry, 2018, 18, 327.	2.6	15
20	“When I Stop My Medication, Everything Goes Wrong” Content Analysis of Interviews with Adolescent Patients Treated with Psychotropic Medication. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 655-662.	1.3	7
21	Non-adherence to Psychotropic Medication Among Adolescents – A Systematic Review of the Literature. Zeitschrift Fur Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2018, 46, 69-78.	0.7	30
22	Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature. Zeitschrift Fur Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2018, 46, 246-263.	0.7	16
23	Critical appraisal of genotype assessment in molybdenum cofactor deficiency. Journal of Inherited Metabolic Disease, 2017, 40, 801-811.	3.6	13
24	Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished – a cross-sectional analysis. International Journal of Methods in Psychiatric Research, 2017, 26, .	2.1	13
25	Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial. Trials, 2016, 17, 141.	1.6	23
26	Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders. Molecular and Cellular Pediatrics, 2015, 2, A1.	1.8	1
27	Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act. Orphanet Journal of Rare Diseases, 2015, 10, 46.	2.7	40
28	Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. Genetics in Medicine, 2015, 17, 965-970.	2.4	45
29	Natural History of Molybdenum Cofactor Deficiency. Neuropediatrics, 2014, 45, .	0.6	0